Display Settings:

Format

Send to:

Choose Destination
    Cell Stem Cell. 2011 May 6;8(5):468-75.

    Target populations for first-in-human embryonic stem cell research in spinal cord injury.

    Source

    Department of Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Scotia B3H 3J5, Canada. frederic.bretzner@dal.ca

    Abstract

    Geron recently announced that it had begun enrolling patients in the world's first-in-human clinical trial involving cells derived from human embryonic stem cells (hESCs). This trial raises important questions regarding the future of hESC-based therapies, especially in spinal cord injury (SCI) patients. We address some safety and efficacy concerns with this research, as well as the ethics of fair subject selection. We consider other populations that might be better for this research: chronic complete SCI patients for a safety trial, subacute incomplete SCI patients for an efficacy trial, and perhaps primary progressive multiple sclerosis (MS) patients for a combined safety and efficacy trial.

    Copyright © 2011 Elsevier Inc. All rights reserved.

    PMID:
    21549321
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk